Crinetics Pharmaceuticals Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 437

Employees

  • Stock Symbol
  • CRNX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $30.85
  • (As of Tuesday Closing)

Crinetics Pharmaceuticals General Information

Description

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 6055 Lusk Boulevard
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 6055 Lusk Boulevard
  • San Diego, CA 92121
  • United States
+1 (858)

Crinetics Pharmaceuticals Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Crinetics Pharmaceuticals Stock Performance

As of 17-Jun-2025, Crinetics Pharmaceuticals’s stock price is $30.85. Its current market cap is $2.89B with 93.7M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$30.85 $31.20 $24.10 - $62.53 $2.89B 93.7M 941K -$3.82

Crinetics Pharmaceuticals Financials Summary

As of 31-Mar-2025, Crinetics Pharmaceuticals has a trailing 12-month revenue of $760K.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 1,818,501 3,931,546 1,874,236 619,692
Revenue 760 1,039 4,013 4,737
EBITDA (373,965) (337,058) (226,867) (167,252)
Net Income (328,252) (298,408) (214,529) (163,918)
Total Assets 1,361,327 1,434,592 635,353 352,176
Total Debt 50,819 51,722 51,728 3,075
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Crinetics Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Crinetics Pharmaceuticals‘s full profile, request access.

Request a free trial

Crinetics Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Crinetics Pharmaceuticals‘s full profile, request access.

Request a free trial

Crinetics Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and comm
Drug Discovery
San Diego, CA
437 As of 2024

Newark, CA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Crinetics Pharmaceuticals Competitors (74)

One of Crinetics Pharmaceuticals’s 74 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Protagonist Therapeutics Formerly VC-backed Newark, CA
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Nektar Therapeutics Formerly VC-backed San Francisco, CA
Abeona Therapeutics Corporation Cleveland, OH
Gilead Sciences Formerly VC-backed Foster City, CA
You’re viewing 5 of 74 competitors. Get the full list »

Crinetics Pharmaceuticals Patents

Crinetics Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12208092-B2 Compositions and methods for administering paltusotine to patients with hepatic impairment Active 28-Mar-2023
US-20240325376-A1 Compositions and methods for administering paltusotine to patients with hepatic impairment Active 28-Mar-2023
US-20240208963-A1 Crystalline melanocortin subtype-2 receptor (mc2r) antagonist Pending 16-Dec-2022
AU-2023395880-A1 Crystalline melanocortin subtype-2 receptor (mc2r) antagonist Pending 16-Dec-2022
US-20240254105-A1 Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof Active 13-Dec-2022 C07D401/14
To view Crinetics Pharmaceuticals’s complete patent history, request access »

Crinetics Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Crinetics Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Crinetics Pharmaceuticals‘s full profile, request access.

Request a free trial

Crinetics Pharmaceuticals Investments (1)

Crinetics Pharmaceuticals’s most recent deal was a Early Stage VC with Radionetics Oncology for . The deal was made on 03-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Radionetics Oncology 03-Jan-2024 Early Stage VC Drug Discovery
To view Crinetics Pharmaceuticals’s complete investments history, request access »

Crinetics Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated October, 22, 2024

38.7 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view Crinetics Pharmaceuticals’s complete esg history, request access »

Crinetics Pharmaceuticals FAQs

  • When was Crinetics Pharmaceuticals founded?

    Crinetics Pharmaceuticals was founded in 2008.

  • Where is Crinetics Pharmaceuticals headquartered?

    Crinetics Pharmaceuticals is headquartered in San Diego, CA.

  • What is the size of Crinetics Pharmaceuticals?

    Crinetics Pharmaceuticals has 437 total employees.

  • What industry is Crinetics Pharmaceuticals in?

    Crinetics Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Crinetics Pharmaceuticals a private or public company?

    Crinetics Pharmaceuticals is a Public company.

  • What is Crinetics Pharmaceuticals’s stock symbol?

    The ticker symbol for Crinetics Pharmaceuticals is CRNX.

  • What is the current stock price of Crinetics Pharmaceuticals?

    As of 17-Jun-2025 the stock price of Crinetics Pharmaceuticals is $30.85.

  • What is the current market cap of Crinetics Pharmaceuticals?

    The current market capitalization of Crinetics Pharmaceuticals is $2.89B.

  • What is Crinetics Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Crinetics Pharmaceuticals is $760K.

  • Who are Crinetics Pharmaceuticals’s competitors?

    Protagonist Therapeutics, Apellis Pharmaceuticals, Nektar Therapeutics, Abeona Therapeutics, and Gilead Sciences are some of the 74 competitors of Crinetics Pharmaceuticals.

  • What is Crinetics Pharmaceuticals’s annual earnings per share (EPS)?

    Crinetics Pharmaceuticals’s EPS for 12 months was -$3.82.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »